Loading…
No business profile yet.
Size Clarity Pharmaceuticals (CU6.AX) is an Australia Health Care company (Medical Specialties) with a market value of $386M, the 292nd largest of 316 Australia companies the cockpit tracks. Shares closed at A$1.50 on 6 Nov 2026.
Performance Over six months the shares fell 47.5%, against -17.5% for the median peer and +4.1% for the Australia market (cap-weighted) — 4th lowest of 19 in its peer set.
Valuation It trades at 3.00× book value against a peer median of 2.05× (6th most expensive of 21).
Price implies The share price implies a return on equity of about 36.6%; Clarity Pharmaceuticals delivers -77.5%, so the price asks more than the business earns today.
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$0 | A$0 | A$0 | A$0 | A$0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -A$283,530 | -A$283,530 | -A$185,083 | -A$153,068 | -A$100,513 |
| EBITDA | -A$119M | -A$119M | -A$78.4M | -A$56.2M | -A$36.1M |
| Net income | -A$107M | -A$107M | -A$64.3M | -A$42.3M | -A$24.6M |
| Free cash flow | -A$92.9M | -A$92.9M | -A$55.0M | -A$43.7M | -A$27.5M |
| Capital expenditure | A$306,922 | A$306,922 | A$182,743 | A$504,005 | A$46,562 |
| Total debt | n/a | A$0 | A$0 | A$0 | A$0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CU6.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.7% | -11.3% | 4th lowest of 21 |
| 6-month return | -47.5% | -17.5% | 4th lowest of 19 |
| Return on equity | -77.5% | 5.7% | 2nd lowest of 20 |
| Price / book | 3.00× | 2.05× | 6th most expensive of 21 |
| ROE the price implies | 36.6% | 13.9% | 3rd most demanding of 20 |
| ROE delivered | -77.5% | 5.6% | lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Clarity Pharmaceuticals CU6.AX | Australia | $386M | -48% | n/a | -78% | 3.00× | 36.6% | -77.5% |
| Nanjing Medlander Medical Technology 688273.SS | China | $385M | -44% | -12% | 6% | 1.94× | 17.7% | 5.6% |
| OrbusNeich Medical 6929.HK | Hong Kong | $389M | -3% | +16% | 11% | 0.93× | 6.1% | 10.5% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $380M | -23% | -8% | 7% | 2.81× | 25.4% | 7.2% |
| Taidoc Technology 4736.TW | Taiwan | $395M | 0% | -6% | 26% | 1.19× | 4.0% | 26.2% |
| InBody 041830.KS | South Korea | $378M | +43% | +21% | 15% | 1.63× | 10.0% | 15.2% |
| Jiangsu Apon Medical Technology 300753.SZ | China | $376M | -27% | -15% | -4% | 3.85× | 20.7% | -4.4% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -246% | 2.16× | 10.2% | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $406M | -13% | +7% | 9% | 2.43× | 10.3% | 9.5% |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 25% | 1.91× | 8.0% | n/a |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $407M | -20% | +46% | 1% | 2.54× | 18.7% | 0.7% |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $407M | -14% | +3% | -25% | 1.03× | 6.0% | -24.8% |
| Cerus CERS | United States | $408M | -23% | +14% | -11% | 5.39× | 62.6% | -10.7% |
| Beijing Succeeder Technology 688338.SS | China | $408M | -15% | -4% | 5% | 1.55× | 13.5% | 5.0% |
| SEERS 458870.KS | South Korea | $409M | -70% | +425% | 92% | 8.08× | 22.9% | 92.0% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 13% | 1.90× | n/a | 13.5% |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $412M | n/a | +19% | 0% | 1.45× | 9.9% | 0.5% |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 16% | 3.16× | 13.9% | 16.1% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $417M | +3% | +12% | 3% | 2.51× | 24.0% | 3.0% |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -3% | 1.44× | 14.1% | -3.2% |
| YD Bio YDES | United States | $423M | -58% | +17% | n/a | 94.54× | 320.5% | n/a |